Pharmacological Attributes of Fenugreek with Special Reference to Alzheimer's Disease
Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..
BACKGROUND: An annual plant, Fenugreek (Trigonellafoenum-graecum L.) has well-known health care benefits in Ayurvedic and Chinese medicine. Its leaves and seeds have alkaloids, amino acids, caumarins, flavonoids, saponins, and other bioactive components. Various pharmacological properties such as antioxidants, hypoglycemic, and hypolipidemic have been attributed to fenugreek. Trigonelline, diosgenin, and 4- hydroxyisoleucine have shown neuroprotection against Alzheimer's disease, and the extract have also been reported to act as an anti-depressant, anti-anxiety, and also regulate cognitive functions. This review highlights various studies carried out on animals as well as on humans for the protective effect against Alzheimer's disease.
METHODS: The data presented in this review is taken from popular search engines, viz, Google Scholar, PubMed, and Scopus. This review highlights the studies and clinical trials performed to show the protective effect of Fenugreek on neurodegenerative diseases with special reference to AD from 2005 to 2023.
RESULTS: Fenugreek improves cognitive deficits by Nrf2-mediated antioxidative pathway and provides neuroprotection against amyloid-beta-induced mitochondria dysfunction. It enhances SOD and catalase activities and scavenges reactive oxygen species to protect the cellular organelle from oxidative stress. It normalizes the tubulin protein and improved axonal growth by regulating nerve growth factors. Fenugreek can also influence metabolism.
DISCUSSION: Fenugreek significantly improves the pathological symptoms of neurodegenerative disease, especially AD and can be used as a therapeutic agent to control disease conditions as evidenced by the review of the literature.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Current Alzheimer research - 20(2023), 2 vom: 23., Seite 71-79 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Varshney, Himanshi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antioxidants |
|---|
| Anmerkungen: |
Date Completed 11.07.2023 Date Revised 18.07.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.2174/1567205020666230525154300 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM357340531 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM357340531 | ||
| 003 | DE-627 | ||
| 005 | 20231226072400.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1567205020666230525154300 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1191.xml |
| 035 | |a (DE-627)NLM357340531 | ||
| 035 | |a (NLM)37231762 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Varshney, Himanshi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Pharmacological Attributes of Fenugreek with Special Reference to Alzheimer's Disease |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 11.07.2023 | ||
| 500 | |a Date Revised 18.07.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net. | ||
| 520 | |a BACKGROUND: An annual plant, Fenugreek (Trigonellafoenum-graecum L.) has well-known health care benefits in Ayurvedic and Chinese medicine. Its leaves and seeds have alkaloids, amino acids, caumarins, flavonoids, saponins, and other bioactive components. Various pharmacological properties such as antioxidants, hypoglycemic, and hypolipidemic have been attributed to fenugreek. Trigonelline, diosgenin, and 4- hydroxyisoleucine have shown neuroprotection against Alzheimer's disease, and the extract have also been reported to act as an anti-depressant, anti-anxiety, and also regulate cognitive functions. This review highlights various studies carried out on animals as well as on humans for the protective effect against Alzheimer's disease | ||
| 520 | |a METHODS: The data presented in this review is taken from popular search engines, viz, Google Scholar, PubMed, and Scopus. This review highlights the studies and clinical trials performed to show the protective effect of Fenugreek on neurodegenerative diseases with special reference to AD from 2005 to 2023 | ||
| 520 | |a RESULTS: Fenugreek improves cognitive deficits by Nrf2-mediated antioxidative pathway and provides neuroprotection against amyloid-beta-induced mitochondria dysfunction. It enhances SOD and catalase activities and scavenges reactive oxygen species to protect the cellular organelle from oxidative stress. It normalizes the tubulin protein and improved axonal growth by regulating nerve growth factors. Fenugreek can also influence metabolism | ||
| 520 | |a DISCUSSION: Fenugreek significantly improves the pathological symptoms of neurodegenerative disease, especially AD and can be used as a therapeutic agent to control disease conditions as evidenced by the review of the literature | ||
| 650 | 4 | |a Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Fenugreek | |
| 650 | 4 | |a diseases | |
| 650 | 4 | |a hypocholesterolemic | |
| 650 | 4 | |a neurological disorders | |
| 650 | 4 | |a oxidative stress | |
| 650 | 4 | |a pharmacology | |
| 650 | 4 | |a therapeutic agent | |
| 650 | 4 | |a traditional medicines | |
| 650 | 7 | |a Plant Extracts |2 NLM | |
| 650 | 7 | |a Antioxidants |2 NLM | |
| 700 | 1 | |a Siddique, Yasir Hasan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current Alzheimer research |d 2004 |g 20(2023), 2 vom: 23., Seite 71-79 |w (DE-627)NLM156140608 |x 1875-5828 |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:2 |g day:23 |g pages:71-79 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2174/1567205020666230525154300 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 2 |b 23 |h 71-79 | ||